<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00091325</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000387801</org_study_id>
    <secondary_id>P30CA023074</secondary_id>
    <secondary_id>UARIZ-HSC-0499</secondary_id>
    <nct_id>NCT00091325</nct_id>
  </id_info>
  <brief_title>Green Tea Extract (Polyphenon E) in Preventing Cancer in Healthy Participants</brief_title>
  <official_title>Phase I Drug Interaction Clinical Study of Polyphenon E</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Arizona</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Arizona</source>
  <brief_summary>
    <textblock>
      RATIONALE: Green tea extract (Polyphenon E) contains ingredients that may prevent the&#xD;
      development of cancer.&#xD;
&#xD;
      PURPOSE: This phase I trial is studying how well green tea extract works in preventing cancer&#xD;
      in healthy participants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  Determine the effect of green tea extract (Polyphenon E) on cytochrome P450 enzyme&#xD;
           activities and glutathione S-transferase activities and levels in healthy participants.&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  Determine the safety and tolerability of this drug in these participants.&#xD;
&#xD;
      OUTLINE: This is an open-label study.&#xD;
&#xD;
      Participants receive oral green tea extract (Polyphenon E) once daily for 4 weeks in the&#xD;
      absence of unacceptable toxicity.&#xD;
&#xD;
      Participants are followed for 2 weeks.&#xD;
&#xD;
      PROJECTED ACCRUAL: A total of 44 participants will be accrued for this study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2004</start_date>
  <primary_completion_date type="Actual">March 2005</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Unspecified Adult Solid Tumor, Protocol Specific</condition>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>defined green tea catechin extract</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Healthy individuals&#xD;
&#xD;
               -  Non-smokers&#xD;
&#xD;
                    -  More than 1 year since smoking cessation&#xD;
&#xD;
                    -  No concurrent smokers&#xD;
&#xD;
               -  No regular consumption of large amounts of alcohol&#xD;
&#xD;
                    -  On average, ≤ 3 alcoholic drinks per week&#xD;
&#xD;
          -  Consumes &lt; 6 cups or glasses of tea per week&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Performance Status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin ≤ 2.0 mg/dL&#xD;
&#xD;
          -  AST or ALT ≤ 2 times normal&#xD;
&#xD;
          -  Alkaline phosphatase ≤ 2 times normal&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine ≤ 1.5 mg/dL&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  Resting systolic blood pressure ≥ 100 mm Hg&#xD;
&#xD;
          -  No hypertension or hypercholesterolemia requiring unscheduled medical visits or&#xD;
             changes in treatment within the past 3 months&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  Willing to refrain from tea and related products and oral herbal/botanical supplements&#xD;
             during study participation&#xD;
&#xD;
          -  Willing to limit the consumption of cruciferous vegetables to ≤ once a week during&#xD;
             study participation&#xD;
&#xD;
          -  Willing to refrain from caffeine-containing food or beverages (e.g., coffee, colas,&#xD;
             chocolate, or over-the-counter medications) for 72 hours before, during, and for 8&#xD;
             hours after study drug administration&#xD;
&#xD;
          -  Willing to refrain from food items that affect drug or carcinogen metabolizing enzymes&#xD;
             (e.g., grapefruit, grapefruit juice, cruciferous vegetables, and food cooked over&#xD;
             charcoal) for 72 hours before, during, and for 8 hours after study drug administration&#xD;
&#xD;
          -  No difficulty swallowing capsules or tablets&#xD;
&#xD;
          -  No metabolic disorder known to affect study drugs&#xD;
&#xD;
          -  No other serious acute or chronic disease (e.g., type I or II diabetes, cystic&#xD;
             fibrosis, or active infection)&#xD;
&#xD;
          -  No known hypersensitivity to green tea or probe drugs (e.g., caffeine,&#xD;
             dextromethorphan, losartan, or buspirone)&#xD;
&#xD;
          -  No invasive cancer (i.e., non-skin cancer) within the past 5 years&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 3 months since prior participation in another clinical intervention study&#xD;
&#xD;
          -  No concurrent medications or supplements that are known P450 enzyme inducers or&#xD;
             inhibitors&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>H. H. Sherry Chow, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Arizona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Cancer Center at University of Arizona Health Sciences Center</name>
      <address>
        <city>Tucson</city>
        <state>Arizona</state>
        <zip>85724</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <study_first_submitted>September 7, 2004</study_first_submitted>
  <study_first_submitted_qc>September 8, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2004</study_first_posted>
  <last_update_submitted>January 15, 2010</last_update_submitted>
  <last_update_submitted_qc>January 15, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 20, 2010</last_update_posted>
  <responsible_party>
    <name_title>H. H. Sherry Chow</name_title>
    <organization>Arizona Cancer Center at University of Arizona Health Sciences Center</organization>
  </responsible_party>
  <keyword>unspecified adult solid tumor, protocol specific</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epigallocatechin gallate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

